Fasenra Pediatric Japan Post-Marketing Study(PMS)

This is a post-marketing safety study for Fasenra (benralizumab) in Japanese children with severe, hard-to-control asthma. It is monitoring how well the medication works and whether it is safe when used in real-world clinical practice in children who are receiving it for the first time. **You may be eligible if...** - Your child is between 6 and under 15 years old - Your child has been diagnosed with bronchial asthma that could not be adequately controlled with previous standard treatments - Your child is being prescribed Fasenra for the first time **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.